Affective disorders: A question of continuing treatment during pregnancy (Review)

Trifu,Simona   Corina; Popescu,Alexandra; Marian, Maria   Alina

doi:10.3892/etm.2020.8989

Affective disorders: A question of continuing treatment during pregnancy (Review)

Authors:
- Simona Corina Trifu
- Alexandra Popescu
- Maria Alina Marian
View Affiliations

Affiliations: Department of Neurosciences, ̔Carol Davila̓ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Psychiatry, ̔Alex. Obregia̓ Clinical Hospital of Psychiatry, 041914 Bucharest, Romania
Published online on: July 13, 2020 https://doi.org/10.3892/etm.2020.8989
Pages: 3474-3482
Copyright: © Trifu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fetal development, especially in the first trimester, has proven to be heavily influenced by external factors, such as chemical intake of medication. Chronic psychiatric treatment might interfere with the anatomical and physiological wellbeing of the fetus, because psychotropic medication proceeds past the placenta, into the amniotic fluid, and can enter breast milk. Hence some of the medications prescribed for mood disorders should be reconsidered during pregnancy, without sub‑optimally treating when it is needed. A literature review is presented which systematically collects modern data and synthesizes previous interdisciplinary research findings on the safety of psychiatric treatment for affective disorders during pregnancy (term‑based) and lactation. Antidepressants and mood stabilizers, fundamental strategies in treating affective disorders, have been classified by the FDA as C respectively D drugs pertaining to their risk, with some exception. Most guidelines recommend pharmacologically treating moderate‑severe depression, preferably with SSRIs. Evidence advocates that drugs should be used during pregnancy only if clearly needed and the benefit outweighs the risk to the fetus. However, guidelines the American College of Obstetricians and Gynecologists state that antidepressants are a preferred first course of treatment and does not take into account the severity of the depression. Among mood‑stabilizers, lithium is considered to be the safest option for pregnant women. Anticonvulsants have a higher risk of teratogenicity compared with lithium, with lamotrigine being the safest one. All mood stabilizers should be recommended in the lowest effective doses. There is controversy regarding the safety of second‑generation antipsychotics during pregnancy and further research is required. Several case reports and meta‑reviews have been published in order to emphasize the safety of electroconvulsive therapy (ECT) during pregnancy, but practitioners still stigmatize this procedure. Evaluating the overall risk‑benefit ratio should be assessed by the medical care provider, taking into consideration current findings.

View Figures

View References

1	American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 87 November 2007: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 110:1179–1198. 2007.PubMed/NCBI View Article : Google Scholar
2	Osborne S, Biaggi A, Chua TE, Du Preez A, Hazelgrove K, Nikkheslat N, Previti G, Zunszain PA, Conroy S and Pariante CM: Antenatal depression programs cortisol stress reactivity in offspring through increased maternal inflammation and cortisol in pregnancy: The Psychiatry Research and Motherhood - Depression (PRAM-D) Study. Psychoneuroendocrinology. 98:211–221. 2018.PubMed/NCBI View Article : Google Scholar
3	Trifu S, Vladuti A and Popescu A: Neuroendocrine aspects of pregnancy and postpartum depression. Acta Endocrinol (Bucur). 15:410–415. 2019.PubMed/NCBI View Article : Google Scholar
4	Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S and Katon WJ: A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 67:1012–1024. 2010.PubMed/NCBI View Article : Google Scholar
5	Azar R and Mercer D: Mild depressive symptoms are associated with elevated C-reactive protein and proinflammatory cytokine levels during early to midgestation: A prospective pilot study. J Womens Health (Larchmt). 22:385–389. 2013.PubMed/NCBI View Article : Google Scholar
6	Davis EP and Sandman CA: The timing of prenatal exposure to maternal cortisol and psychosocial stress is associated with human infant cognitive development. Child Dev. 81:131–148. 2010.PubMed/NCBI View Article : Google Scholar
7	Braithwaite EC, Murphy SE and Ramchandani PG: Effects of prenatal depressive symptoms on maternal and infant cortisol reactivity. Arch Women Ment Health. 19:581–590. 2016.PubMed/NCBI View Article : Google Scholar
8	Molenaar NM, Bais B, Lambregtse-van den Berg MP, Mulder CL, Howell EA, Fox NS, Rommel AS, Bergink V and Kamperman AM: The international prevalence of antidepressant use before, during, and after pregnancy: A systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord. 264:82–89. 2020.PubMed/NCBI View Article : Google Scholar
9	Simoncelli M, Martin BZ and Bérard A: Antidepressant use during pregnancy: A critical systematic review of the literature. Curr Drug Saf. 5:153–170. 2010.PubMed/NCBI View Article : Google Scholar
10	Trifu S: Neuroendocrine insights into burnout syndrome. Acta Endocrinol (Bucur). 15:404–405. 2019.PubMed/NCBI View Article : Google Scholar
11	Clabault H, Flipo D, Guibourdenche J, Fournier T, Sanderson JT and Vaillancourt C: Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization. Toxicol Appl Pharmacol. 349:8–20. 2018.PubMed/NCBI View Article : Google Scholar
12	Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C and Poulsen HE: Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open. 2(e001148)2012.PubMed/NCBI View Article : Google Scholar
13	Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, et al: Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 74:e293–e308. 2013.PubMed/NCBI View Article : Google Scholar
14	Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteijn JM, Morgan M, Garne E, Hansen AV, Klungsøyr K, et al: Selective serotonin reuptake inhibitor (SSRI) antidepressants in pregnancy and congenital anomalies: Analysis of linked databases in Wales, Norway and Funen, Denmark. PLoS One. 11(e0165122)2016.PubMed/NCBI View Article : Google Scholar
15	Wurst KE, Poole C, Ephross SA and Olshan AF: First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 88:159–170. 2010.PubMed/NCBI View Article : Google Scholar
16	Malm H, Artama M, Gissler M and Ritvanen A: Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 118:111–120. 2011.PubMed/NCBI View Article : Google Scholar
17	Källén BAJ and Olausson PO: Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 79:301–308. 2007.PubMed/NCBI View Article : Google Scholar
18	Pop A, Lupu DI, Cherfan J, Kiss B and Loghin F: Estrogenic/anti-estrogenic activity of selected selective serotonin reuptake inhibitors. Clujul Med. 88:381–385. 2015.PubMed/NCBI View Article : Google Scholar
19	Nikfar S, Rahimi R, Hendoiee N and Abdollahi M: Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis. Daru. 20(75)2012.PubMed/NCBI View Article : Google Scholar
20	Trifu S, Mihailescu R, Stegarescu S and Ion I: Evolutional perspective over some key-aspects in psychiatry. In: Theoretical and Applied in Psychology (SICAP23): Psychology and Ongoing Development. Zamosteanu A (ed.) Medimond s.r.l., Bologna, pp179-182, 2015.
21	Eke AC, Saccone G and Berghella V: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: A systematic review and meta-analysis. BJOG. 123:1900–1907. 2016.PubMed/NCBI View Article : Google Scholar
22	Levinson-Castiel R, Merlob P, Linder N, Sirota L and Klinger G: Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 160:173–176. 2006.PubMed/NCBI View Article : Google Scholar
23	Man KK, Tong HH, Wong LY, Chan EW, Simonoff E and Wong IC: Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies. Neurosci Biobehav Rev. 49:82–89. 2015.PubMed/NCBI View Article : Google Scholar
24	Morales DR, Slattery J, Evans S and Kurz X: Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: Systematic review of observational studies and methodological considerations. BMC Med. 16(6)2018.PubMed/NCBI View Article : Google Scholar
25	Pinheiro E, Bogen DL, Hoxha D, Ciolino JD and Wisner KL: Sertraline and breastfeeding: Review and meta-analysis. Arch Women Ment Health. 18:139–146. 2015.PubMed/NCBI View Article : Google Scholar
26	Paulzen M, Goecke TW, Stickeler E, Gründer G and Schoretsanitis G: Sertraline in pregnancy - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord. 212:1–6. 2017.PubMed/NCBI View Article : Google Scholar
27	Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A and Koren G: Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 193:2004–2009. 2005.PubMed/NCBI View Article : Google Scholar
28	Grossmann CK, Weitzner B, Pistelli A, Many A, Lessing J and Koren G: Escitalopram use in pregnancy: An observational cohort study. Am J Obstet Gynecol. 206(S58)2012.
29	Pereira JD, Caricati-Neto A, Jurkiewicz A and Jurkiewicz NH: Decreased noradrenergic and serotonergic reactivity of vas deferens of newborn rats from mothers treated with the serotonin reuptake inhibitor fluoxetine during pregnancy and breast-feeding. Life Sci. 81:1501–1508. 2007.PubMed/NCBI View Article : Google Scholar
30	Smit-Rigter LA, Noorlander CW, von Oerthel L, Chameau P, Smidt MP and van Hooft JA: Prenatal fluoxetine exposure induces life-long serotonin 5-HT₃ receptor-dependent cortical abnormalities and anxiety-like behaviour. Neuropharmacology. 62:865–870. 2012.PubMed/NCBI View Article : Google Scholar
31	Glazova NY, Merchieva SA, Volodina MA, Sebentsova EA, Manchenko DM, Kudrun VS and Levitskaya NG: Effects of neonatal fluvoxamine administration on the physical development and activity of the serotoninergic system in white rats. Acta Naturae. 6:98–105. 2014.PubMed/NCBI
32	Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A and Koren G: Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 29:918–926. 2007.PubMed/NCBI View Article : Google Scholar
33	Paulus WE: Risk of congenital malformations after maternal treatment with venlafaxine in early pregnancy. Reprod Toxicol. 37(87)2013.
34	Dandjinou M, Sheehy O and Bérard A: Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: A nested case-control study. BMJ Open. 9(e025908)2019.PubMed/NCBI View Article : Google Scholar
35	Holland J and Brown R: Neonatal venlafaxine discontinuation syndrome: A mini-review. Eur J Paediatr Neurol. 21:264–268. 2017.PubMed/NCBI View Article : Google Scholar
36	Huybrechts KF, Bateman BT, Pawar A, Bessette LG, Mogun H, Levin R, Li H, Motsko S, Scantamburlo Fernandes MF, Upadhyaya HP, et al: Maternal and fetal outcomes following exposure to duloxetine in pregnancy: Cohort study. BMJ. 368(237)2020.PubMed/NCBI View Article : Google Scholar
37	Gentile S: Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf. 13:207–225. 2014.PubMed/NCBI View Article : Google Scholar
38	National Collaborating Centre for Mental Health (UK): Antenatal and Postnatal Mental Health: The NICE Guideline on Clinical Management and Service Guidance. British Psychological Society, Leicester, 2007. https://pubmed.ncbi.nlm.nih.gov/21678630/.
39	Armstrong C: ACOG Guidelines on psychiatric medication use during pregnancy and lactation. Am Fam Physician. 78:772–778. 2008.
40	Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S and Einarson A: Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am J Obstet Gynecol. 192:932–936. 2005.PubMed/NCBI View Article : Google Scholar
41	Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM and Walker AM: Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 16:474–484. 2007.PubMed/NCBI View Article : Google Scholar
42	Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y and Koren G: A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry. 48:106–110. 2003.PubMed/NCBI View Article : Google Scholar
43	Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, Kennedy D, Voyer Lavigne S, De Santis M and Einarson A: Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. J Clin Psychiatry. 67:1280–1284. 2006.PubMed/NCBI View Article : Google Scholar
44	Trifu S, Delcuescu C and Boer CM: Psychosomatics and psychical tension (clinical research). Procedia Soc Behav Sci. 33:128–132. 2012.
45	Khan SJ, Fersh ME, Ernst C, Klipstein K, Albertini ES and Lusskin SI: Bipolar disorder in pregnancy and postpartum: Principles of management. Curr Psychiatry Rep. 18(13)2016.PubMed/NCBI View Article : Google Scholar
46	Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA and Bergink V: Risk of postpartum relapse in bipolar disorder and postpartum psychosis: A systematic review and meta-analysis. Am J Psychiatry. 173:117–127. 2016.PubMed/NCBI View Article : Google Scholar
47	Gentile S: Lithium in pregnancy: The need to treat, the duty to ensure safety. Expert Opin Drug Saf. 11:425–437. 2012.PubMed/NCBI View Article : Google Scholar
48	Deligiannidis KM, Byatt N and Freeman MP: Pharmacotherapy for mood disorders in pregnancy: A review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 34:244–255. 2014.PubMed/NCBI View Article : Google Scholar
49	Forsberg L, Berglund G, Naver L, Ljungdahl M, Adler M and Wide K: Bipolar disorder and pregnancy-neurodevelopmental outcome of children exposed to maternal illness with or without lithium during pregnancy. Arch Dis Child. 97 (Suppl 2):A184–A185. 2012.
50	van der Lugt NM, van de Maat JS, van Kamp IL, Knoppert-van der Klein EA, Hovens JG and Walther FJ: Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev. 88:375–378. 2012.PubMed/NCBI View Article : Google Scholar
51	Cohen LS, Friedman JM, Jefferson JW, Johnson EM and Weiner ML: A reevaluation of risk of in utero exposure to lithium. JAMA. 271:146–150. 1994.PubMed/NCBI
52	Trifu S: Dissociative identity disorder Psychotic functioning and impairment of growing-up processes. J Educ Sci Psychol. 9:102–108. 2019.
53	Grover S and Avasthi A: Mood stabilizers in pregnancy and lactation. Indian J Psychiatry. 57 (Suppl 2):S308–S323. 2015.PubMed/NCBI View Article : Google Scholar
54	Horton S, Tuerk A, Cook D, Cook J and Dhurjati P: Maximum recommended dosage of lithium for pregnant women based on a PBPK model for lithium absorption. Adv Bioinforma. 2012(352729)2012.PubMed/NCBI View Article : Google Scholar
55	Veroniki AA, Rios P, Cogo E, Straus SE, Finkelstein Y, Kealey R, Reynen E, Soobiah C, Thavorn K, Hutton B, et al: Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: A systematic review and network meta-analysis. BMJ Open. 7(e017248)2017.PubMed/NCBI View Article : Google Scholar
56	Womersley K: Prescription of sodium valproate as a mood stabiliser in pregnancy. Psychiatr Danub. 29 (Suppl 3):679–684. 2017.PubMed/NCBI
57	Haskey C and Galbally M: Mood stabilizers in pregnancy and child developmental outcomes: A systematic review. Aust N Z J Psychiatry. 51:1087–1097. 2017.PubMed/NCBI View Article : Google Scholar
58	Deshmukh U, Adams J, Macklin EA, Dhillon R, McCarthy KD, Dworetzky B, Klein A and Holmes LB: Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine. Neurotoxicol Teratol. 54:5–14. 2016.PubMed/NCBI View Article : Google Scholar
59	McVearry KM, Gaillard WD, VanMeter J and Meador KJ: A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav. 16:609–616. 2009.PubMed/NCBI View Article : Google Scholar
60	Gentile S: Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: A systematic review with regulatory repercussions. CNS Spectr. 19:305–315. 2014.PubMed/NCBI View Article : Google Scholar
61	Koch S, Lösche G, Jager-Romän E, Jakob S, Rating D, Deichl A and Helge H: Major and minor birth malformations and antiepileptic drugs. Neurology. 42 (Suppl 5):83–88. 1992.PubMed/NCBI
62	Kong L, Zhou T, Wang B, Gao Z and Wang C: The risks associated with the use of lamotrigine during pregnancy. Int J Psychiatry Clin Pract. 22:2–5. 2018.PubMed/NCBI View Article : Google Scholar
63	Diav-Citrin O, Shechtman S, Zvi N, Finkel-Pekarsky V and Ornoy A: Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Res. 109:1196–1203. 2017.PubMed/NCBI View Article : Google Scholar
64	Yasam VR, Jakki SL, Senthil V, Eswaramoorthy M, Shanmuganathan S, Arjunan K and Nanjan MJ: A pharmacological overview of lamotrigine for the treatment of epilepsy. Expert Rev Clin Pharmacol. 9:1533–1546. 2016.PubMed/NCBI View Article : Google Scholar
65	Cohen-Israel M, Berger I, Martonovich EY, Klinger G, Stahl B and Linder N: Short- and long-term complications of in utero exposure to lamotrigine. Br J Clin Pharmacol. 84:189–194. 2018.PubMed/NCBI View Article : Google Scholar
66	Dolk H, Wang H, Loane M, Morris J, Garne E, Addor MC, Arriola L, Bakker M, Barisic I, Doray B, et al: Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology. 86:1716–1725. 2016.PubMed/NCBI View Article : Google Scholar
67	Pariente G, Leibson T, Shulman T, Adams-Webber T, Barzilay E and Nulman I: Pregnancy outcomes following in utero exposure to lamotrigine: A systematic review and meta-analysis. CNS Drugs. 31:439–450. 2017.PubMed/NCBI View Article : Google Scholar
68	Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E and Vajda F: EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 10:609–617. 2011.PubMed/NCBI View Article : Google Scholar
69	Tomson T, Landmark CJ and Battino D: Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications. Epilepsia. 54:405–414. 2013.PubMed/NCBI View Article : Google Scholar
70	Ding Y, Tan X, Zhang S and Guo Y: Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. Brain Behav. 9(e01315)2019.PubMed/NCBI View Article : Google Scholar
71	Tran TA, Leppik IE, Blesi K, Sathanandan ST and Remmel R: Lamotrigine clearance during pregnancy. Neurology. 59:251–255. 2002.PubMed/NCBI View Article : Google Scholar
72	Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, García-Fiñana M, Gummery A, Kneen R, Loring DW, Mawer G, et al: Liverpool and Manchester Neurodevelopment Group: IQ at 6 years after in utero exposure to antiepileptic drugs: A controlled cohort study. Neurology. 84:382–390. 2015.PubMed/NCBI View Article : Google Scholar
73	Frey B, Schubiger G and Musy JP: Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr. 150:136–138. 1990.PubMed/NCBI View Article : Google Scholar
74	Ladea M and Prelipceanu D: Markers of vulnerability in schizophrenia. J Med Life. 2:155–164. 2009.PubMed/NCBI
75	De Santis M, De Luca C, Mappa I, Cesari E, Quattrocchi T, Spagnuolo T, Visconti D and Caruso A: Antiepileptic drugs during pregnancy: Pharmacokinetics and transplacental transfer. Curr Pharm Biotechnol. 12:781–788. 2011.PubMed/NCBI View Article : Google Scholar
76	Chen CY, Li X, Ma LY, Wu PH, Zhou Y, Feng Q and Cui YM: In utero oxcarbazepine exposure and neonatal abstinence syndrome: Case report and brief review of the literature. Pharmacotherapy. 37:e71–e75. 2017.PubMed/NCBI View Article : Google Scholar
77	Mines D, Tennis P, Curkendall SM, Li DK, Peterson C, Andrews EB, Calingaert B, Chen H, Deshpande G, Esposito DB, et al: Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 23:1017–1025. 2014.PubMed/NCBI View Article : Google Scholar
78	Castilla-Puentes R, Ford L, Manera L, Kwarta RF Jr, Ascher S and Li Q: Topiramate monotherapy use in women with and without epilepsy: Pregnancy and neonatal outcomes. Epilepsy Res. 108:717–724. 2014.PubMed/NCBI View Article : Google Scholar
79	Veiby G, Daltveit AK, Engelsen BA and Gilhus NE: Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 261:579–588. 2014.PubMed/NCBI View Article : Google Scholar
80	Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, Han JY, Matsui D, Etwell F, Einarson TR, et al: Pregnancy outcomes following gabapentin use: Results of a prospective comparative cohort study. Neurology. 80:1565–1570. 2013.PubMed/NCBI View Article : Google Scholar
81	Damkier P and Videbech P: The safety of second-generation antipsychotics during pregnancy: A clinically focused review. CNS Drugs. 32:351–366. 2018.PubMed/NCBI View Article : Google Scholar
82	Bellantuono C, Di Massimo G, Mauro A, Martellini M and Nardi B: Aripiprazole in pregnancy: A review of literature. Riv Psichiatr. 50:8–11. 2015.PubMed/NCBI View Article : Google Scholar : (In Italian).
83	Galbally M, Frayne J, Watson SJ and Snellen M: Aripiprazole and pregnancy: A retrospective, multicentre study. J Affect Disord. 238:593–596. 2018.PubMed/NCBI View Article : Google Scholar
84	Ballester-Gracia I, Pérez-Almarcha M, Galvez-Llompart A and Hernandez-Viadel M: Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: A case report. BMC Pharmacol Toxicol. 20(52)2019.PubMed/NCBI View Article : Google Scholar
85	Pinheiro EA, Wisner KL and Clark CT: Quetiapine dose adjustments in pregnant and postpartum women with bipolar disorder. J Clin Psychopharmacol. 38:89–91. 2018.PubMed/NCBI View Article : Google Scholar
86	Cohen LS, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S and Freeman MP: Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry. 175:1225–1231. 2018.PubMed/NCBI View Article : Google Scholar
87	Spinelli MG: Accurate assessment of risk of major malformations in infants with first-trimester exposure to quetiapine. Am J Psychiatry. 175:1161–1162. 2018.PubMed/NCBI View Article : Google Scholar
88	Brunner E, Falk DM, Jones M, Dey DK and Shatapathy CC: Olanzapine in pregnancy and breastfeeding: A review of data from global safety surveillance. BMC Pharmacol Toxicol. 14(38)2013.PubMed/NCBI View Article : Google Scholar
89	Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H and Huybrechts KF: Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 175:564–574. 2018.PubMed/NCBI View Article : Google Scholar
90	Pierre D, Péricaud A, Guerby P, Castel A, Schmitt L and Yrondi A: Bitemporal electroconvulsive therapy during the second trimester of pregnancy in bipolar disorders: A case report. J ECT. 36:e14–e15. 2020.PubMed/NCBI View Article : Google Scholar
91	Ward HB, Fromson JA, Cooper JJ, De Oliveira G and Almeida M: Recommendations for the use of ECT in pregnancy: Literature review and proposed clinical protocol. Arch Women Ment Health. 21:715–722. 2018.PubMed/NCBI View Article : Google Scholar
92	Coshal S, Jones K, Coverdale J and Livingston R: An overview of reviews on the safety of electroconvulsive therapy administered during pregnancy. J Psychiatr Pract. 25:2–6. 2019.PubMed/NCBI View Article : Google Scholar
93	Calaway K, Coshal S, Jones K, Coverdale J and Livingston R: A systematic review of the safety of electroconvulsive therapy use during the first timester of pregnancy. J ECT. 32:230–235. 2016.PubMed/NCBI View Article : Google Scholar